Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia
BACKGROUND: Cytarabine (cytosine arabinoside, ara-C) is a chemotherapeutical agent used in the treatment of pediatric acute lymphoblastic leukemia (ALL). Adverse drug reactions, such as interpatient variability in sensitivity to ara-C, are considerable and may cause difficulties during chemotherapy....
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2015
|
| Sorozat: | PEDIATRIC BLOOD & CANCER
62 No. 4 |
| doi: | 10.1002/pbc.25379 |
| mtmt: | 2807591 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11920 |
| LEADER | 02646nab a2200325 i 4500 | ||
|---|---|---|---|
| 001 | publ11920 | ||
| 005 | 20200210134106.0 | ||
| 008 | 170911s2015 hu o 0|| zxx d | ||
| 022 | |a 1545-5009 | ||
| 024 | 7 | |a 10.1002/pbc.25379 |2 doi | |
| 024 | 7 | |a 2807591 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Gábor Krisztina | |
| 245 | 1 | 0 | |a Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia |h [elektronikus dokumentum] / |c Gábor Krisztina |
| 260 | |c 2015 | ||
| 300 | |a 622-628 | ||
| 490 | 0 | |a PEDIATRIC BLOOD & CANCER |v 62 No. 4 | |
| 520 | 3 | |a BACKGROUND: Cytarabine (cytosine arabinoside, ara-C) is a chemotherapeutical agent used in the treatment of pediatric acute lymphoblastic leukemia (ALL). Adverse drug reactions, such as interpatient variability in sensitivity to ara-C, are considerable and may cause difficulties during chemotherapy. Single nucleotide polymorphisms (SNPs) can play a significant role in modifying nucleoside-drug pharmacokinetics and pharmacodynamics and thus the development of adverse effects. Our aim was to determine whether polymorphisms in genes encoding transporters and enzymes responsible for the metabolism of ara-C are associated with toxicity and clinical outcome in a patient population with childhood ALL. PROCEDURE: We studied 8 SNPs in the CDA, DCK, DCTD, SLC28A3, and SLC29A1 genes in 144 patients with childhood acute lymphoblastic leukemia treated according to ALLIC BFM 1990, 1995 and 2002 protocols. RESULTS: DCK rs12648166 and DCK rs4694362 SNPs were associated with hematologic toxicity (OR = 2.63, CI 95% = 1.37-5.04, P = 0.0036 and OR = 2.53, CI 95% = 1.34-4.80, P = 0.0044, respectively). CONCLUSIONS: Our results indicate that DCK polymorphisms might be important genetic risk factors for hematologic toxicity during ALL treatment with ara-C. Individualized chemotherapy based on genetic profiling may help to optimize ara-C dosing, leading to improvements in clinical outcome and reduced toxicity. Pediatr Blood Cancer 2014;9999:1-7(c) 2015 Wiley Periodicals, Inc. | |
| 700 | 0 | 1 | |a Schermann Géza |e aut |
| 700 | 0 | 2 | |a Lautner-Csorba Orsolya |e aut |
| 700 | 0 | 2 | |a Rárosi Ferenc |e aut |
| 700 | 0 | 2 | |a Erdélyi Dániel |e aut |
| 700 | 0 | 2 | |a Börcsökné Endreffy Emőke |e aut |
| 700 | 0 | 2 | |a Berek Krisztina |e aut |
| 700 | 0 | 2 | |a Bartyik Katalin |e aut |
| 700 | 0 | 2 | |a Bereczki Csaba |e aut |
| 700 | 0 | 2 | |a Szalai Csaba |e aut |
| 700 | 0 | 2 | |a Semsei Ágnes F. |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/11920/1/O_Impact_of_SNPS_of_Cytarabine_metabolic_genes_2015_Gabor_u.pdf |z Dokumentum-elérés |